IL-10-related T cell-derived inducible factor (IL-22, also known as IL-TIF) is a cytokine that was originally identified in mouse as an IL-9 inducible gene in T cells and mast cells and shows 22% amino acid identity with IL-10. Additionally, IL-22 is induced by IL-9 in thymic lymphomas and by lectins in freshly isolated splenocytes. IL-22 is found in both the thymus and brain, which suggests that the role of this factor is not restricted to the immune system. IL-22 is a ligand for CRF2-4, a member of the class II cytokine receptor family. In contrast to IL-10, IL-22 does not inhibit the production of proinflammatory cytokines by monocytes in response to lipopolysaccharide nor does it impact IL-10 function on monocytes, but it has modest inhibitory effects on IL-4 production from Th2 T cells.

IL-22 Polyclonal Antibody detects endogenous levels of IL-22 protein.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-1:2000, ELISA: 1:10000. Not yet tested in other applications.

IL-22 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at http://www.abbkine.com/product/il-22-polyclonal-antibody-abp57408.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.